Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 537.52 is 674% above its 5-year average of 69.48, near the high end of its 5-year range (-23.40–537.52).
172.40% above its 12-month average of 197.33.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 114.36.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:31:29.708Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
537.52
EARNINGS PER SHARE (EPS) AVG TTM
197.33
EARNINGS PER SHARE (EPS) AVG 3Y
123.75
EARNINGS PER SHARE (EPS) AVG 5Y
69.48
EARNINGS PER SHARE (EPS) AVG 10Y
-129.71
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+172.40%
CURRENT VS 3Y AVG
+334.36%
CURRENT VS 5Y AVG
+673.63%
CURRENT VS 10Y AVG
+514.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Enlivex Therapeutics Ltd.
Market Cap
$6.29M
Earnings Per Share (EPS)
537.52
TTM Avg
197.33
3Y Avg
123.75
5Y Avg
69.48
Market Cap
$6.10M
Earnings Per Share (EPS)
-2.92
TTM Avg
-6.51
3Y Avg
-19.53
5Y Avg
-13.36
Market Cap
$6.25M
Earnings Per Share (EPS)
-4.57
TTM Avg
-13.10
3Y Avg
-16.05
5Y Avg
-14.80
Market Cap
$6.19M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.92
3Y Avg
-0.62
5Y Avg
-0.53
Market Cap
$6.46M
Earnings Per Share (EPS)
-1.26
TTM Avg
-1.73
3Y Avg
-1.08
5Y Avg
-0.87
Market Cap
$6.41M
Earnings Per Share (EPS)
-2.52
TTM Avg
-4.28
3Y Avg
-38.17
5Y Avg
-84.63
Market Cap
$5.59M
Earnings Per Share (EPS)
-3.55
TTM Avg
-11.46
3Y Avg
-17.07
5Y Avg
-17.09
Market Cap
$5.54M
Earnings Per Share (EPS)
-9.46
TTM Avg
-14.22
3Y Avg
-49.51
5Y Avg
-78.92
Market Cap
$6.72M
Earnings Per Share (EPS)
-16.00
TTM Avg
-9.75
3Y Avg
-5.91
5Y Avg
-4.74
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $6.29M | 537.52 | 197.33 | 123.75 | 69.48 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -2.92 | -6.51 | -19.53 | -13.36 |
| Femasys Inc. (FEMY)vs › | $6.25M | -4.57 | -13.10 | -16.05 | -14.80 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.19M | N/A | -0.92 | -0.62 | -0.53 |
| Biomerica, Inc. (BMRA)vs › | $6.46M | -1.26 | -1.73 | -1.08 | -0.87 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.41M | -2.52 | -4.28 | -38.17 | -84.63 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | -3.55 | -11.46 | -17.07 | -17.09 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | -9.46 | -14.22 | -49.51 | -78.92 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -16.00 | -9.75 | -5.91 | -4.74 |
| Aclarion, Inc. (ACON)vs › | $6.80M | -7.60 | -3746.91 | -66167.96 | -82548.30 |
Trailing EPS (TTM)
$537.52
Forward EPS (Est.)
$-1.15
P/E Ratio
0.0
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 405.60 |
| 2024-12-31 | -10.95 |
| 2023-12-31 | -23.40 |
| 2021-12-31 | -8.10 |
| 2020-12-31 | -15.75 |
| 2019-12-31 | -17.55 |
| 2018-12-31 | -159.45 |
| 2017-12-31 | -215.25 |
| 2016-12-31 | -604.35 |
| 2015-12-31 | -647.85 |
| 2014-12-31 | -343.65 |
| 2013-12-31 | -63.15 |
| 2012-12-31 | -0.13 |
